Pharmaceutical Investing Revive Therapeutics Provides Corporate Update on its Pharmaceutical Initiatives
Pharmaceutical Investing Revive Therapeutics Provides an Update on its Psilocybin-Based Pharmaceutical Program
Pharmaceutical Investing Revive Therapeutics Announces U.S. FDA Recommendation to Proceed Directly Into A Phase 3 Confirmatory Clinical Trial
Pharmaceutical Investing Revive Therapeutics Announces Research Partnership Agreement with the University of Wisconsin-Madison
Pharmaceutical Investing Revive Therapeutics Partners with Complete Phytochemical Solutions to Advance Research Initiatives for Psilocybin-Based Pharmaceutical Products
Pharmaceutical Investing Revive Therapeutics Announces Closing of Second Tranche of Brokered Private Placement
Pharmaceutical Investing Revive Therapeutics Engages Novotech as Asia-Pacific CRO for Bucillamine in the Treatment of Infectious Diseases
Cannabis Investing Revive Therapeutics Provides Corporate Update on its COVID-19 and Infectious Diseases Programs
Cannabis Investing Revive Therapeutics Explores the use of Bucillamine as a Novel Treatment for Infectious Diseases Including COVID-19
Life Science Investing Revive Provides Update on its Clinical Development Plan for Cannabidiol in the Treatment of Autoimmune Hepatitis
RUA GOLD Completes the Second Phase of Surface Exploration and Drill Targeting at the Glamorgan Project, New Zealand
Radiopharm Theranostics Accelerates 177Lu-RAD204 Phase 1 Dose Escalation Clinical Trial Based on Positive Recommendation from Data Safety and Monitoring Committee
Finlay Minerals Appoints an Executive Chairman, President & CEO, and Vice President, Corporate Development
